\
&
Contact us
This was 3 years ago
Locationvirtual
ProgrammesThe European Innovation Council (EIC) and European Medicines Agency (EMA) are organising an Info Day. Participants will get to know the wide range of support services provided by EMA to researchers and SMEs active in research and innovation in the pharmaceutical and med-tech sectors. Speakers will talk about how to engage with EMA at different development milestones, and on the range of EMA support services. Benefits of the Innovation Task Force (ITF) services, PRIME and Scientific Advice, as well as practical details on how to prepare and submit applications, will be tackled. The event will entail testimonials from academic researchers and companies funded by the EIC Pathfinder and Accelerator programmes on their experience with EMA services.
EIC grantees and future EIC applicants are strongly encouraged to participate. The event is also open to researchers and SMEs funded by other EU programmes.
This event is relevant if:
The event is free of charge and no registration is required. The Info Day will be broadcasted on this web page
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.